Search for: "AstraZeneca AB" Results 21 - 40 of 92
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Mar 2012, 5:32 am by Mark Summerfield
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520 (14 December 2011) Interlocutory injunctions – prima facie case – balance of convenience – relevance of delay by patentee, complexity of proceedings, and parties’ conduct and obligations In the first Federal Court decision to follow the ruling of the Full Court in Samsung v Apple (see Samsung v Apple – A Closer Look at the Appeal Decision) Justice Rares has granted a preliminary injunction to… [read post]
20 Jan 2008, 6:55 pm
AstraZeneca AB et al. v. [read post]
19 Jul 2011, 2:49 am by tracey
Supreme Court Duncombe & Ors v Secretary of State for Children, Schools and Families [2011] UKSC 36 (15 July 2011) High Court (Patents Court) Ranbaxy (UK) Ltd v Astrazeneca AB [2011] EWHC 1831 (Pat) (15 July 2011) Select Healthcare (UK) Ltd v Cromptons Healthcare Ltd & Anor [2011] EWHC 1830 (Pat) (15 July 2011) Source: www.bailii.org   [read post]
8 Dec 2021, 8:52 am by Lawrence B. Ebert
The outcome AstraZeneca AB and AstraZeneca Pharmaceuticals LP (collectively, “AstraZeneca”) sued Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. [read post]
9 Dec 2021, 7:15 am by Logan Murr
The decision relates to AstraZeneca AB’s and AstraZeneca Pharmaceuticals LP’s (collectively “AstraZeneca”) lawsuit against Mylan and Kindeva Drug Delivery LP (collectively “Mylan”) for infringing all claims of U.S. [read post]
5 Dec 2011, 9:59 pm by Patent Docs
In Ranbaxy (UK) Ltd v AstraZeneca AB, the England and Wales High Court considered the scope of "Swiss" medical use claims. [read post]
25 Jul 2007, 3:15 pm
AstraZeneca sued after Andrx filed an Abbreviated New Drug Applications (ANDA) seeking FDA approval to market generic versions of Toprol-XL ®, which Astra claimed infringed its patents pursuant to 35 U.S.C. [read post]
12 May 2017, 9:05 am by Tom Lamb
., AstraZeneca Pharmaceuticals LP, AstraZeneca LP, AstraZeneca PLC, and AstraZeneca AB (collectively, Bristol-Myers/AstraZeneca), which developed, manufactured, and marketed the drugs, failed to adequately test the drugs and warn of their risks. [read post]
6 Apr 2017, 9:59 pm by Patent Docs
AstraZeneca AB PTAB Petition: IPR2017-00631; filed January 9, 2017. [read post]
3 May 2017, 9:59 pm by Patent Docs
InnoPharma Licensing, LLC v AstraZeneca AB PTAB Petition: IPR2017-00900; filed February 17, 2017. [read post]
5 Feb 2021, 5:30 am by Ralf Michaels
The first difficulty is thus to identify the parties to the APA.[8] According the APA, the parties are AstraZeneca AB and the European Commission “acting on behalf and in the name of the member states of the European Union”. [read post]
13 Jan 2009, 8:41 am
AstraZeneca AB: This case involves a burden of proof. [read post]
29 Aug 2015, 9:08 pm by Mark Summerfield
At 10.15am this coming Wednesday (2 September 2015) the Australian High Court will hand down its decision in the appeal by AstraZeneca AB against last year’s ruling, by a a special five-judge panel of the Federal Court of Australia, that its two patents relating to the cholesterol-lowering drug marketed as CRESTOR (having the active ingredient rosuvastatin) are invalid.The decision will be significant in clarifying the law relating to obviousness in Australia. [read post]
13 Jul 2010, 2:31 am by war
321/05 AstraZeneca AB v Commission which has been conveniently summarised by Linklaters and Gibson Dunn. [read post]
9 Mar 2015, 1:46 pm by Tom Lamb
And from the FDA announcement about this Endocrinologic and Metabolic Drugs Advisory Committee Meeting, as regards the Agenda: During the morning session, the committee will discuss the results of the cardiovascular outcomes trial (CVOT), Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus, for new drug application (NDA) 22350, Onglyza (saxagliptin) and NDA 200678, Kombiglyze XR (saxagliptin and metformin HCl extended-release) tablets manufactured/marketed… [read post]